679 related articles for article (PubMed ID: 20569105)
21. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
22. Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?
Meirow D; Raz I; Yossepowitch O; Brzezinski A; Rosler A; Schenker JG; Berry EM
Hum Reprod; 1996 Sep; 11(9):1848-53. PubMed ID: 8921052
[TBL] [Abstract][Full Text] [Related]
23. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like factor 3 -- a new hormone related to polycystic ovary syndrome?
Szydlarska D; Grzesiuk W; Trybuch A; Kondracka A; Kowalik I; Bar-Andziak E
Endokrynol Pol; 2012; 63(5):356-61. PubMed ID: 23115068
[TBL] [Abstract][Full Text] [Related]
25. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the association of vitamin D deficiency with gonadotropins and sex hormone in obese and non-obese women with polycystic ovary syndrome.
Velija-Ašimi Z
Med Glas (Zenica); 2014 Feb; 11(1):170-6. PubMed ID: 24496360
[TBL] [Abstract][Full Text] [Related]
27. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.
Pinola P; Puukka K; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Lindén Hirschberg A; Ravn P; Skovsager Andersen M; Glintborg D; Mellembakken JR; Ruokonen A; Tapanainen JS; Morin-Papunen LC
Fertil Steril; 2017 Mar; 107(3):788-795.e2. PubMed ID: 28089571
[TBL] [Abstract][Full Text] [Related]
28. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women.
Maitra A; Pingle RR; Menon PS; Naik V; Gokral JS; Meherji PK
Int J Fertil Womens Med; 2001; 46(5):271-7. PubMed ID: 11720200
[TBL] [Abstract][Full Text] [Related]
29. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
Holte J; Bergh T; Berne C; Lithell H
Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
[TBL] [Abstract][Full Text] [Related]
30. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
[TBL] [Abstract][Full Text] [Related]
31. Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome.
Cortet-Rudelli C; Pigny P; Decanter C; Leroy M; Maunoury-Lefebvre C; Thomas-Desrousseaux P; Dewailly D
Fertil Steril; 2002 Feb; 77(2):281-7. PubMed ID: 11821084
[TBL] [Abstract][Full Text] [Related]
32. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
33. Intrinsic factors rather than vitamin D deficiency are related to insulin resistance in lean women with polycystic ovary syndrome.
Sahin S; Eroglu M; Selcuk S; Turkgeldi L; Kozali S; Davutoglu S; Muhcu M
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2851-6. PubMed ID: 25339479
[TBL] [Abstract][Full Text] [Related]
34. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?
Ozkaya E; Cakir E; Cinar M; Kara F; Baser E; Cakir C; Kucukozkan T
Gynecol Endocrinol; 2012 Jun; 28(6):468-71. PubMed ID: 22103710
[TBL] [Abstract][Full Text] [Related]
35. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.
Hernández-Mijares A; Bañuls C; Gómez-Balaguer M; Bergoglio M; Víctor VM; Rocha M
Eur J Clin Invest; 2013 Jun; 43(6):549-56. PubMed ID: 23528141
[TBL] [Abstract][Full Text] [Related]
36. The influence of obesity on androstenedione to testosterone ratio in women with polycystic ovary syndrome (PCOS) and hyperandrogenemia.
Misichronis G; Georgopoulos NA; Marioli DJ; Armeni AK; Katsikis I; Piouka AD; Saltamavros AD; Roupas ND; Panidis D
Gynecol Endocrinol; 2012 Apr; 28(4):249-52. PubMed ID: 21970600
[TBL] [Abstract][Full Text] [Related]
37. Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome.
Sam S; Scoccia B; Yalamanchi S; Mazzone T
Hum Reprod; 2015 Jun; 30(6):1358-64. PubMed ID: 25857311
[TBL] [Abstract][Full Text] [Related]
38. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B.
Chu MC; Carmina E; Wang J; Lobo RA
Fertil Steril; 2005 Dec; 84(6):1685-8. PubMed ID: 16359965
[TBL] [Abstract][Full Text] [Related]
39. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.
Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM
Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313
[TBL] [Abstract][Full Text] [Related]
40. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
